Your browser doesn't support javascript.
loading
Effects of cytotoxic T-lymphocyte-associated protein 4 compared to TNF inhibitors on lipid profile: Results from an observational multicentre rheumatoid arthritis cohort.
Atzeni, Fabiola; Cacciapaglia, Fabio; Galloways, James; Manfredi, Andreina; Sakellariou, Garifallia; Norton, Sam; Gremese, Elisa; Spinelli, Francesca Romana; Viapiana, Ombretta; Piga, Matteo; Erre, Gian Luca; Bartoloni Bocci, Elena.
Afiliación
  • Atzeni F; Rheumatology Unit, University of Messina, Messina, Italy. Electronic address: atzenifabiola@hotmail.com.
  • Cacciapaglia F; Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari, Bari, Italy.
  • Galloways J; Centre for Rheumatic Diseases, King's College London, London, UK.
  • Manfredi A; Rheumatology Unit, Azienda Ospedaliera Universitaria Policlinico of Modena, Italy.
  • Sakellariou G; Department of Internal Medicine and Therapeutics, University of Pavia, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy.
  • Norton S; Centre for Rheumatic Diseases, King's College London, London, UK.
  • Gremese E; Division of Clinical Immunology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore-Rome, 00168 Rome, Italy.
  • Spinelli FR; Rheumatology Unit, Department of Clinical Internal, Anaesthesiologic and Cardiovascular Science, Sapienza University of Rome, Rome, Italy.
  • Viapiana O; UOC Reumatologia, Università degli Studi di Verona, Italy.
  • Piga M; Dipartimento Scienze Mediche e Sanità Pubblica, Università di Cagliari, Italy.
  • Erre GL; Dipartimento di Medicina, Chirurgia e Farmacia, Università degli Studi di Sassari, Italy.
  • Bartoloni Bocci E; Rheumatology Unit, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Autoimmun Rev ; 23(2): 103478, 2023 Nov 11.
Article en En | MEDLINE | ID: mdl-37956778
AIM: To evaluate the impact of selective cytotoxic T-lymphocyte-associated protein 4 (CTLA-4Ig) compared to tumor necrosis factor inhibitors (TNFi) on cardiovascular (CV) clinical and laboratory outcomes in patients with rheumatoid arthritis (RA). METHODS: We performed a prospective observational multicenter study of RA patients included in the "Cardiovascular Obesity and Rheumatic DISease (CORDIS)" Study Group database, collecting demographic, clinical, and laboratory data of those starting a CTLA-4Ig or TNFi at baseline, 6-month, and 12-month follow-up. RESULTS: Of the 206 RA patients without previous CV events enrolled in the study, 64 received a CTLA-4Ig and 142 a TNFi. The two groups did not differ in age, gender, or smoking habits, and the prevalence of hypertension, diabetes, and metabolic syndrome was similar. Over a follow-up period of 12 months, although no significant differences were found in the disease activity course, we observed that LDL cholesterol levels slightly decreased only in the CTLA-4Ig-treated patients. CONCLUSIONS: Patients treated with both CTLA-4Ig and TNFi did not differ in disease activity response and changes in traditional CV risk factors after 12 months of treatment. However, CTL-A-4Ig treatment is associated with a favorable change in lipid profile at 12-month follow-up.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Autoimmun Rev Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2023 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Autoimmun Rev Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2023 Tipo del documento: Article Pais de publicación: Países Bajos